Summary

In one aspect, there is provided a compound of formula (I)



(I)

wherein,

R^1 is -C_{1-3}alkyl or -C_{1-3}haloalkyl;

R^2 is selected from -NHR^4, -C_{1-5}alkyl, -C_{1-5}haloalkyl, halogen and -S-C_{1-3}alkyl;

R^3 is a 5-12 membered heteroaryl, which group is substituted with -X-R^{10} and optionally further substituted with one or more groups independently selected from R^9;

R^4 is selected from -C_{1-5}alkyl and 5-12 memebered heterocycloalkyl, which heterocycloalkyl can be optionally substituted with one or more groups independently selected from R^5;

R^5 is selected from -C_{1-5}alkyl, -C_{1-5}haloalkyl and -C_{1-3}alkylene-O-C_{1-3}alkyl;

R^9 is selected from -C_{1-5}alkyl, -O-C_{1-5}alkyl, -$N(C_{1-5}alkyl)_2$, halogen, -C_{1-3}alkylene-O-C_{1-3}alkyl, -C_{1-5}alkylene-N(-C_{1-5}alkyl, -C_{1-5}alkyl), 5-12 memebered heterocycloalkyl,wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from =O, -C_{1-3}alkyl, or

R^9 is selected from -C_{6-10}aryl and 5-12 memebered heteroaryl, wherein the aryl and heteroaryl groups can be optionally and independently substituted with one ore

more groups selected from halogen, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -C_{1-3}haloalkyl, -O-C_{1-3}haloalkyl, -N(C_{1-5}alkyl, C_{1-5}alkyl) and
-NH-C_{1-5}alkyl;

X is -C_{1-3}alkylene- or -O-;

R^{10} is -C_{6-10}aryl or 5-12 membered heteroaryl, each of which groups can be optionally substituted with one or more groups selected from halogen, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -C_{1-3}haloalkyl, -O-C_{1-3}haloalkyl;

wherein the compounds of formula (I) may be optionally be present in the form of salts.

In another aspect, there is provided a compound of general formula (I) as defined herein - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or prevention of cancer.

In another aspect, there is provided a pharmaceutical preparation comprising as active substance one or more compounds of general formula (I) as defined herein optionally in combination with conventional excipients and/or carriers.

In another aspect, there is provided a pharmaceutical preparation comprising a compound of general formula (I) as defined herein - or one of the pharmaceutically acceptable salts thereof - and at least one other cytostatic or cytotoxic active substance, different from formula (I).

In another aspect, there is provided a compound of general formula (I) as defined herein - or the pharmaceutically acceptable salts thereof - for use as medicaments.

In another aspect, there is provided a compound of general formula (I) as defined herein - or the pharmaceutically acceptable salts thereof - for use in the treatment of hematopoietic malignancies.

In another aspect, there is provided a compound of general formula (I) as defined herein - or the pharmaceutically acceptable salts thereof - for use in the treatment of AML or MM.

In another aspect, there is provided a compound of general formula (I) as defined herein - or the pharmaceutically acceptable salts thereof - for use in the treatment of lung, liver, colon, brain, thyroid, pancreas, breast, ovary and prostate cancer.